NCCN Revises Breast Cancer Treatment Guidelines
HOLLYWOOD, FL - March 1, 2002 - Oncologists, oncology nurses, and
patients now have a more comprehensive resource in their fight against
breast cancer. The National Comprehensive Cancer Network (NCCN)
presented the 2002 Breast Cancer Practice Guidelines at their 7th
annual conference in Hollywood, Florida today.
The NCCN Practice Guidelines in Oncology are the recognized standard
for clinical policy in the field of oncology. The guidelines are
continuously monitored and updated with the most up-to-date information
regarding cancer care. The Breast Cancer Treatment Guidelines have
been revised twice in the past year. A full update was completed
in December 2001 and then, the Guidelines were updated again in
January 2002 based on the release of new data at the 2001 San Antonio
Breast Cancer Symposium.
The 2002 Breast Cancer Treatment Guideline changes were based on
review and discussion of recently published evidence. Major changes
in 2002 include elaboration on the role of sentinel node biopsy,
and updates in systemic therapies including the role of hormonal
therapy with the aromatase inhibitors in postmenopausal women and
LH-RH agonists in premenopausal women for metastatic disease.
Trial results that led to the January 2002 update include the ATAC
(Arimidex and Tamoxifen Alone or in Combination) trial results,
which demonstrate that Arimidex (anastrozole) provides superior
disease-free survival and a favorable toxicity profile compared
to tamoxifen as adjuvant therapy for hormone receptor-positive breast
cancer in postmenopausal women. The ATAC results were compiled after
a median of 33.3 months follow-up and a median duration of treatment
of 30.7 months. Tamoxifen, which has been on the market for over
20 years The revised guidelines thus state that anastrozole may
be considered as an option to tamoxifen after discussion of the
available data between the physician and patient.
"Since new developments in cancer research are truly happening
all the time, we revise our Practice Guidelines continuously,"
said Rodger Winn, MD Chairman of the NCCN Guidelines Steering Committee.
"NCCN's new Internet version of the guidelines allows our panels
to respond to treatment advances almost immediately."
In addition to offering the most authoritative and up-to-date information
in cancer care, the NCCN Guidelines performance is measured and
integrated into the NCCN Outcomes Database, which allows the NCCN
to translate the Guidelines into a powerful resource for continuously
improving the effectiveness and efficiency of cancer care.
Physicians interested in the NCCN Practice Guidelines may view
them online at www.nccn.org or request a CD-ROM by sending a letter
to NCCN, 500 Old York Road, Suite 250, Jenkintown, PA 19046, or
faxing a letter of request to 215-690-0280.
The NCCN is an alliance of 19 of the world's leading cancer centers,
established in 1995 to provide the state-of-the-art in cancer care
to the greatest number of patients in need.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- University of Wisconsin Carbone Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital